Denecimig (Mim8) for Hemophilia A, with or without inhibitors
One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Hemophilia A. Unsubscribe anytime.
The FDA is expected to decide on Denecimig for Hemophilia A, with or without inhibitors in an undisclosed window, under a BLA from Novo Nordisk.
What is being decided
Novo Nordisk has a BLA under FDA review for Denecimig (Mim8) in Hemophilia A, with or without inhibitors. Under-the-skin injection to prevent bleeding episodes in adults and children with hemophilia A, including people with inhibitors (antibodies that stop standard factor VIII replacement from working). It mimics the job of factor VIII, the clotting protein people with hemophilia A lack, and can be given once a month, every two weeks or weekly from a single-use prefilled pen. Novo submitted the application in September 2025 and had guided to a US decision in Q3 2026. On October 2, 2026 Novo said the FDA has extended its review because of ongoing remediation at the manufacturing facility following a pre-license inspection, and has not given a new timeline for a decision; the FDA identified no deficiencies in the clinical efficacy or safety data. Novo now aims to launch in the US in the first half of 2027, pending the decision. In the pivotal FRONTIER 2 trial it significantly reduced bleeding rates compared with prior factor prophylaxis or on-demand treatment. Europe's CHMP recommended approval under the name Frehemgo on September 17, 2026.
Who this decision matters to
Hemophilia A is an X-linked bleeding disorder caused by deficiency or dysfunction of clotting factor VIII. Severity depends on factor levels, ranging from mild to severe hemorrhage. Modern factor replacement therapy and novel bypassing agents have transformed outcomes and quality of life.
Prevalence: 1 in 4,000 to 5,000 males worldwide; very rare in females. See our full Hemophilia A page for current treatments, recruiting trials, and community resources.
About the drug
Denecimig: bispecific antibody that bridges factor IXa and factor X, mimicking activated factor VIII. Our full Denecimig profile covers how it works, side effects in plain language, and its trial history.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Hemophilia A treatment stands today
Read our full Hemophilia A treatment summary
Factor VIII replacement therapy (plasma-derived or recombinant formulations including third and fourth generation products) remains the standard treatment, with dosing based on severity and bleeding event. Prophylactic therapy (regular infusions starting in childhood) prevents hemarthrosis and dramatically improves long-term joint outcomes, with early prophylaxis (before age 2-3 years) preserving normal joint function.
Bypassing agents including activated prothrombin complex concentrate (aPCC) and recombinant factor VIIa (rFVIIa) manage inhibitor development (alloimmunization occurs in 20-30% of patients). Several non-factor medicines, given as injections under the skin, are now FDA approved to prevent bleeds.
Emicizumab (Hemlibra), which does the job of missing factor VIII, was approved in November 2017. Marstacimab (Hympavzi) was approved in October 2024 for people 12 and older without inhibitors (antibodies that block replacement factor) and was expanded in June 2026 to people 6 and older with or without inhibitors.
Concizumab (Alhemo) was approved in December 2024 for people 12 and older with inhibitors and was expanded in July 2025 to those without inhibitors. Fitusiran (Qfitlia) was approved in March 2025 for people 12 and older with or without inhibitors.
The one-time gene therapy valoctocogene roxaparvovec (Roctavian) was FDA approved in June 2023 for some adults with severe hemophilia A, but on February 23, 2026 BioMarin announced it is voluntarily withdrawing Roctavian from the market after it could not find a buyer, a decision the company said was not related to safety or effectiveness. Prophylaxis initiated in childhood dramatically improves long-term joint health and quality of life.
Work with hemophilia specialists at comprehensive care centers.
The Hemophilia A page has every treatment and trial →Meanwhile, 80 Hemophilia A trials are recruiting
Whatever the FDA decides here, research on Hemophilia A does not stop. A few currently enrolling studies, US sites first:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Hemophilia A. Unsubscribe anytime.
Our coverage
Frequently asked questions
When will the FDA decide on Denecimig?
Novo Nordisk has not disclosed a decision date.
Who disclosed it: Novo Nordisk. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
What is Denecimig being reviewed for?
Novo Nordisk submitted a BLA for Denecimig in Hemophilia A, with or without inhibitors.
What to know: Under-the-skin injection to prevent bleeding episodes in adults and children with hemophilia A, including people with inhibitors (antibodies that stop standard factor VIII replacement from working). It mimics the job of factor VIII, the clotting protein people with hemophilia A lack, and can be given once a month, every two weeks or weekly from a single-use prefilled pen. Novo submitted the application in September 2025 and had guided to a US decision in Q3 2026. On October 2, 2026 Novo said the FDA has extended its review because of ongoing remediation at the manufacturing facility following a pre-license inspection, and has not given a new timeline for a decision; the FDA identified no deficiencies in the clinical efficacy or safety data. Novo now aims to launch in the US in the first half of 2027, pending the decision. In the pivotal FRONTIER 2 trial it significantly reduced bleeding rates compared with prior factor prophylaxis or on-demand treatment. Europe's CHMP recommended approval under the name Frehemgo on September 17, 2026.
How it works: Bispecific antibody that bridges factor IXa and factor X, mimicking activated factor VIII.
More: the Denecimig drug page explains it in plain language.
Is there already an FDA-approved treatment for Hemophilia A?
Yes. Trial Friend's drug list includes 4 FDA-approved drugs for Hemophilia A.
Approved: Hemlibra (emicizumab), Alhemo (concizumab), Hympavzi (marstacimab), Qfitlia (fitusiran).
Check: the Hemophilia A page also searches FDA drug labels for approved treatments.
What did the Denecimig trials show?
FRONTIER2 (NCT05053139) included 254 people aged 12 and older in its main analysis with hemophilia A, 12% of them with inhibitors, and compared 26 weeks of monthly or weekly denecimig with each person's prior treatment. Monthly denecimig cut treated bleeds by about 99% versus on-demand treatment and about 43% versus prior factor prophylaxis; weekly denecimig cut them by about 96% and 54%.
More: the Denecimig drug page has the full trial history and sources.
What are the side effects of Denecimig?
In the Phase 3 FRONTIER2 trial, injection site reactions were reported by 10% of participants and occurred with 2.6% of injections. No blood clots and no clinical evidence of neutralizing antibodies against denecimig were reported.
More: the Denecimig drug page lists the warnings in full.
Can I get Denecimig before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 80 Hemophilia A trials are recruiting now. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Novo Nordisk directly. Registered programs are listed on ClinicalTrials.gov.
How much will Denecimig cost?
Novo Nordisk has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Denecimig decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Novo Nordisk company announcement, October 2, 2026. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.